Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 187.5% | -9.1% | 56.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.6% | 57.6% | 81.6% | 76.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 62.1% | 21.2% | 45.8% | 27.4% |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 49.9% | -5.3% | 16.9% | 33.3% |
| EPS Diluted | 8.12 | -0.31 | 1.05 | 1.28 |
| % Growth | 2,719.4% | -129.5% | -18% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |